Cambridge Medical Technologies

Cambridge Medical Technologies is a private, pre-revenue developer of a novel diagnostic platform for continuous biomarker monitoring. Its core technology involves minimally invasive, nano-scale devices that sample interstitial fluid and use electrochemistry to detect blood analytes, targeting the need for real-time, trended patient data in chronic disease management. With operations in the UK, US, and Japan, the company is led by a seasoned executive team with deep experience in medtech, finance, and engineering, positioning it to address a significant gap in the digital health diagnostics market.

Nano-scale fluid sampling and electrochemical detection system for non-invasive, continuous monitoring of blood analytes via subcutaneous interstitial fluid.

CMT operates in the highly competitive continuous biosensing market, competing directly with giants like Abbott (Freestyle Libre), Dexcom (CGM), and Roche, as well as numerous startups. Its differentiation hinges on potentially monitoring a broader panel of biomarkers beyond glucose. However, these competitors have vast resources, established manufacturing, and proven commercial and reimbursement track records.